MRLI

A combined approach to smart imaging agents- using heterometallic lanthanide complexes as diagnostics

Coordinatore	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD    more  Organization address address: University Offices, Wellington Square city: OXFORD postcode: OX1 2JD contact info Titolo: Ms. Nome: Linda Cognome: Polik Email: send email Telefono: +44(0)1865289811 Fax: +44(0)1865289801
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	177˙740 €
EC contributo	177˙740 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2007-2-1-IEF
Funding Scheme	MC-IEF
Anno di inizio	2008
Periodo (anno-mese-giorno)	2008-04-01   -   2009-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD  Organization address address: University Offices, Wellington Square city: OXFORD postcode: OX1 2JD contact info Titolo: Ms. Nome: Linda Cognome: Polik Email: send email Telefono: +44(0)1865289811 Fax: +44(0)1865289801	UK (OXFORD)	coordinator	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'This proposal aims to develop new contrast agents, derived from heterobinuclear lanthanide complexes, for use in imaging. These will combine the interesting properties of gadolinium complexes used in magnetic resonance imaging with those of luminescent lanthanide ions used in time-resolved micrscopy and assay applications. Our aims are fourfold, namely: To develop synthetic strategies which allow us to prepare heterometallic complexes suitable for multimodal imaging, using multi-component reactions or approaches involving diazo coupling to access these complexes; To develop methods by which nucleotide or PNA recognition domains are used to facilitate rapid transport of imaging components and programmed self-assembly of the multimodal imaging edifice at the target site; To develop switchable multi-modal agents, whose properties are altered by chemical or electrochemical change; and To prepare and study a range of multimodal imaging agents that can be targeted to cell surface receptors, and which have sufficiently high relaxivity to provide meaningful MRI contrast at low concentrations.'